Clinical trial

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

NCT04363164

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2020-08-19

PhasePHASE2

Study timeline

Study start (actual)2020-08-19Date precision: day

Registry last updated2026-07-17

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Castration Resistant Metastatic Prostate Cancerunresolved

Interventions

Testosterone cypionateDRUG · verified · RxNorm: testosterone cypionate

EnzalutamideDRUG · verified · RxNorm: enzalutamide

Testosterone enanthateDRUG · verified · RxNorm: testosterone enanthate

Sponsors & collaborators

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkinslead sponsor

United States Department of Defensecollaborator

Mapped research locations

BostonMassachusetts, United States1 BaltimoreMaryland, United States1 SeattleWashington, United States1 San DiegoCalifornia, United States1 MinneapolisMinnesota, United States1 OmahaNebraska, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04363164 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.